Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Looks Beyond Crestor to HIV Platform

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Shionogi still has a few years to reap the benefits of Crestor royalties from AstraZeneca, but the looming generic substitution of rival Lipitor is forcing the company to prepare for a slowdown of its blockbuster drug. But according to Macquarie Equities Research, revised ex-U.S. Crestor prospects, strong pipeline prospects and recent launches could position Shionogi well in the near term
Advertisement

Related Content

Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
Green Cross Obtains South Korean Approval For BioCryst Influenza Therapy Peramivir
Green Cross Obtains South Korean Approval For BioCryst Influenza Therapy Peramivir
Shionogi Spurns Europe, Places Bets On Asia For Global Expansion - Bio Expo Japan
Shionogi Spurns Europe, Places Bets On Asia For Global Expansion - Bio Expo Japan
Daiichi Sankyo, Shionogi Profits Increase; Dainippon Sumitomo Expands In China - Japanese Pharma Earnings Roundup (Part 2 Of 2)
Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate
With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate
Advertisement
UsernamePublicRestriction

Register

SC075101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel